Asegua Therapeutics
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.aseguaresources.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Asegua Therapeutics
EPCLUSA (sofosbuvir and velpatasvir) is indicated for the treatment of adults and pediatric patients with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis. The medication offers a cure rate of SVR12 (HCV RNA LLOQ 12 weeks after treatment completion) and provides important safety information regarding the risk of hepatitis B virus reactivation. EPCLUSA is designed to provide efficacy, adherence, safety, and dosing information for healthcare professionals and patients in the United States.Explore more
Popular SearchesAsegua Therapeutics LLCSIC Code 28,283NAICS Code 32,325Show more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Asegua Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Asegua Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Asegua Therapeutics
Website visits: Recent activity has been detected on your website
Check if Asegua Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Asegua Therapeutics is spiking on competitors!
Earning: See what the market has to say on Asegua Therapeutics recently announced quarterly report
Click to see if Asegua Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Asegua Therapeutics has new funding data
Product Launch: Get notified when Asegua Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Asegua Therapeutics
Compare insights from companies similar to Asegua Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Asegua Therapeutics
<$5M
11-50
Private
-
-
N/A
Asegua Therapeutics Tech Stack
A closer look at the technologies used by Asegua Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Asegua Therapeutics
Sign Up For FreeTo access detailed company insights
EPCLUSA (sofosbuvir and velpatasvir) is indicated for the treatment of adults and pediatric patients with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis. The medication offers a cure rate of SVR12 (HCV RNA LLOQ 12 weeks after treatment completion) and provides important safety information rega... Read More
